Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.61 | N/A | -6.41% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.61 | N/A | -6.41% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over the EPS miss but emphasized their commitment to long-term strategies. They did not provide specific revenue guidance.
Management acknowledged challenges in meeting EPS expectations.
No specific revenue figures were provided, indicating uncertainty.
The focus remains on long-term growth despite short-term setbacks.
Alnylam Pharmaceuticals reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock still rose by 0.77%, suggesting that investors may be optimistic about the company's long-term prospects despite the EPS miss. The lack of revenue figures and guidance may contribute to ongoing uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Jul 30, 2018